The UK stand together trial: protocol for a multicentre cluster randomised controlled trial to evaluate the effectiveness and cost-effectiveness of KiVa to reduce bullying in primary schools.
Bullying
Children
Cluster randomised controlled trial
Cost-effectiveness
Economic evaluation
Effectiveness
Intervention
KiVa
Process evaluation
School
School intervention
Violence prevention
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
29 03 2022
29 03 2022
Historique:
received:
06
01
2022
accepted:
25
01
2022
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Reducing bullying is a public health priority. KiVa, a school-based anti-bullying programme, is effective in reducing bullying in Finland and requires rigorous testing in other countries, including the UK. This trial aims to test the effectiveness and cost-effectiveness of KiVa in reducing child reported bullying in UK schools compared to usual practice. The trial is currently on-going. Recruitment commenced in October 2019, however due to COVID-19 pandemic and resulting school closures was re-started in October 2020. Design: Two-arm pragmatic multicentre cluster randomised controlled trial with an embedded process and cost-effectiveness evaluation. 116 primary schools from four areas; North Wales, West Midlands, South East and South West England. Outcomes will be assessed at student level (ages 7-11 years; n = approximately 13,000 students). KiVa is a whole school programme with universal actions that places a strong emphasis on changing bystander behaviour alongside indicated actions that provide consistent strategies for dealing with incidents of bullying. KiVa will be implemented over one academic year. Usual practice. Student-level bullying-victimisation assessed through self-report using the extensively used and validated Olweus Bully/Victim questionnaire at baseline and 12-month follow-up. student-level bullying-perpetration; student mental health and emotional well-being; student level of, and roles in, bullying; school related well-being; school attendance and academic attainment; and teachers' self-efficacy in dealing with bullying, mental well-being, and burnout. 116 schools (58 per arm) with an assumed ICC of 0.02 will provide 90% power to identify a relative reduction of 22% with a 5% significance level. recruited schools will be randomised on 1:1 basis stratified by Key-Stage 2 size and free school meal status. Process evaluation: assess implementation fidelity, identify influences on KiVa implementation, and examine intervention mechanisms. Economic evaluation: Self-reported victimisation, Child Health Utility 9D, Client Service Receipt Inventory, frequency of services used, and intervention costs. The health economic analysis will be conducted from a schools and societal perspective. This two-arm pragmatic multicentre cluster randomised controlled trial will evaluate the KiVa anti-bullying intervention to generate evidence of the effectiveness, cost-effectiveness and scalability of the programme in the UK. Our integrated process evaluation will assess implementation fidelity, identify influences on KiVa implementation across England and Wales and examine intervention mechanisms. The integrated health economic analysis will be conducted from a schools and societal perspective. Our trial will also provide evidence regarding the programme impact on inequalities by testing whether KiVa is effective across the socio-economic gradient. Trials ISRCTN 12300853 Date assigned 11/02/2020.
Sections du résumé
BACKGROUND
Reducing bullying is a public health priority. KiVa, a school-based anti-bullying programme, is effective in reducing bullying in Finland and requires rigorous testing in other countries, including the UK. This trial aims to test the effectiveness and cost-effectiveness of KiVa in reducing child reported bullying in UK schools compared to usual practice. The trial is currently on-going. Recruitment commenced in October 2019, however due to COVID-19 pandemic and resulting school closures was re-started in October 2020.
METHODS
Design: Two-arm pragmatic multicentre cluster randomised controlled trial with an embedded process and cost-effectiveness evaluation.
PARTICIPANTS
116 primary schools from four areas; North Wales, West Midlands, South East and South West England. Outcomes will be assessed at student level (ages 7-11 years; n = approximately 13,000 students).
INTERVENTION
KiVa is a whole school programme with universal actions that places a strong emphasis on changing bystander behaviour alongside indicated actions that provide consistent strategies for dealing with incidents of bullying. KiVa will be implemented over one academic year.
COMPARATOR
Usual practice.
PRIMARY OUTCOME
Student-level bullying-victimisation assessed through self-report using the extensively used and validated Olweus Bully/Victim questionnaire at baseline and 12-month follow-up.
SECONDARY OUTCOMES
student-level bullying-perpetration; student mental health and emotional well-being; student level of, and roles in, bullying; school related well-being; school attendance and academic attainment; and teachers' self-efficacy in dealing with bullying, mental well-being, and burnout.
SAMPLE SIZE
116 schools (58 per arm) with an assumed ICC of 0.02 will provide 90% power to identify a relative reduction of 22% with a 5% significance level.
RANDOMISATION
recruited schools will be randomised on 1:1 basis stratified by Key-Stage 2 size and free school meal status. Process evaluation: assess implementation fidelity, identify influences on KiVa implementation, and examine intervention mechanisms. Economic evaluation: Self-reported victimisation, Child Health Utility 9D, Client Service Receipt Inventory, frequency of services used, and intervention costs. The health economic analysis will be conducted from a schools and societal perspective.
DISCUSSION
This two-arm pragmatic multicentre cluster randomised controlled trial will evaluate the KiVa anti-bullying intervention to generate evidence of the effectiveness, cost-effectiveness and scalability of the programme in the UK. Our integrated process evaluation will assess implementation fidelity, identify influences on KiVa implementation across England and Wales and examine intervention mechanisms. The integrated health economic analysis will be conducted from a schools and societal perspective. Our trial will also provide evidence regarding the programme impact on inequalities by testing whether KiVa is effective across the socio-economic gradient.
TRIAL REGISTRATION
Trials ISRCTN 12300853 Date assigned 11/02/2020.
Identifiants
pubmed: 35351054
doi: 10.1186/s12889-022-12642-x
pii: 10.1186/s12889-022-12642-x
pmc: PMC8961482
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
608Subventions
Organisme : Public Health Research Programme
ID : NIHR 17-92-11
Investigateurs
Mackenzie Fong
(M)
Hayley Gains
(H)
Helin Gosalia
(H)
Anwen Jones
(A)
Bryony Longdon
(B)
Fiona Lugg-Widger
(F)
Siobhan B Mitchell
(SB)
Caitlin Murray
(C)
Naomi Rose
(N)
Holly Whiteley
(H)
Katie Taiyari
(K)
Melanie Varley
(M)
Margiad E Williams
(ME)
Informations de copyright
© 2022. The Author(s).
Références
Prev Sci. 2020 Jul;21(5):615-626
pubmed: 32240480
Am J Psychiatry. 2014 Jul;171(7):777-84
pubmed: 24743774
Prev Sci. 2020 Jul;21(5):627-638
pubmed: 32394049
Clin Child Psychol Psychiatry. 2018 Jan;23(1):25-41
pubmed: 28135832
BMJ. 2015 Jun 02;350:h2469
pubmed: 26037951
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
Soc Sci Med. 2018 Jul;208:134-141
pubmed: 29803971
J Am Acad Child Adolesc Psychiatry. 2001 Nov;40(11):1337-45
pubmed: 11699809
Med Decis Making. 2012 Mar-Apr;32(2):350-61
pubmed: 22016450
Adm Policy Ment Health. 2011 Jan;38(1):44-53
pubmed: 20967495
BMJ. 2004 Mar 20;328(7441):702-8
pubmed: 15031246
J Child Psychol Psychiatry. 1994 Oct;35(7):1171-90
pubmed: 7806605
Prev Sci. 2018 Aug;19(6):728-737
pubmed: 29728796
Sch Psychol Q. 2016 Mar;31(1):8-27
pubmed: 25866866
J Consult Clin Psychol. 2011 Dec;79(6):796-805
pubmed: 21967491
BMJ. 2012 Apr 26;344:e2683
pubmed: 22539176
Child Dev. 2011 Jan-Feb;82(1):311-30
pubmed: 21291444
BMJ. 2017 Aug 2;358:j3453
pubmed: 28768629
Qual Life Res. 2012 May;21(4):717-25
pubmed: 21837445
Clin Psychol Rev. 2008 Mar;28(3):451-71
pubmed: 17720288
J Abnorm Child Psychol. 2012 Feb;40(2):289-300
pubmed: 21822630
J Intellect Disabil Res. 2002 Feb;46(Pt 2):144-50
pubmed: 11869385
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Health Qual Life Outcomes. 2007 Nov 27;5:63
pubmed: 18042300
Value Health. 2021 Apr;24(4):539-547
pubmed: 33840432
Stat Methods Med Res. 2005 Aug;14(4):369-95
pubmed: 16178138
Prev Sci. 2016 Nov;17(8):1012-1023
pubmed: 27488457